Literature DB >> 14551271

Hepatic perfusion as a predictor of mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites.

Eric Walser1, Orhan S Ozkan, Syed Raza, Roger Soloway, Leka Gajula.   

Abstract

PURPOSE: To determine whether hepatic perfusion patterns predict mortality after transjugular intrahepatic portosystemic shunt (TIPS) creation in patients with severe ascites.
MATERIALS AND METHODS: This retrospective study included 22 patients who had enhanced cine magnetic resonance (MR) imaging performed immediately before TIPS creation in the angled coronal plane including the left kidney, liver, and main portal vein. Regions of interest were centered over the liver and kidney, and perfusion curves were generated and reviewed before the standard TIPS procedure was performed. Four patients did not undergo TIPS creation as a result of very poor hepatic perfusion by MR. All patients were followed clinically and by ultrasound surveillance of their shunt.
RESULTS: Eleven patients died within 6 months, including all four patients who did not have a TIPS because of MR evidence of poor hepatic perfusion. Of these 11 patients, eight (73%) had unfavorable liver flow consisting of diminished enhancement compared to the kidney and early peak enhancement of less than 50 seconds. The surviving patients all showed a delayed peak enhancement of greater than 50 seconds.
CONCLUSIONS: In patients undergoing TIPS creation for refractory ascites, blunted arterial-type hepatic enhancement is a poor prognostic sign. Cine MR imaging with evaluation of hepatic perfusion can be performed and reviewed before the TIPS procedure. Alternative techniques for ascites reduction may be preferred for patients with unfavorable hepatic perfusion.

Entities:  

Mesh:

Year:  2003        PMID: 14551271     DOI: 10.1097/01.rvi.0000092665.72261.b0

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

1.  Transjugular intrahepatic portosystemic shunt-related complications and practical solutions.

Authors:  Renato Ripamonti; Hector Ferral; Marc Alonzo; Nilesh H Patel
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

2.  Cirrhotic cardiomyopathy is less prevalent in patients with Budd-Chiari syndrome than cirrhosis of liver.

Authors:  Akash Shukla; Pratin Bhatt; Deepak Kumar Gupta; Tejas Modi; Jatin Patel; Milind Phadke; Krantikumar Rathod; Megha Meshram; S J Bhatia
Journal:  Indian J Gastroenterol       Date:  2018-01-24

3.  Hepatic perfusion and hemodynamic effects of transjugular intrahepatic portosystemic shunts.

Authors:  Eric M Walser; Michael Nguyen
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

Review 4.  Current status and strategies for viral hepatitis control in Korea.

Authors:  Dong Hyun Sinn; Eun Ju Cho; Ji Hoon Kim; Do Young Kim; Yoon Jun Kim; Moon Seok Choi
Journal:  Clin Mol Hepatol       Date:  2017-09-19

5.  Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: An observational study (STROBE compliant).

Authors:  Yue-Meng Wan; Yu-Hua Li; Hua-Mei Wu; Zhi-Yuan Xu; Ying Xu; Li-Hong Yang; Xi-Nan Wu; Jin-Hui Yang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.